Cart is empty
View Cart
Subtotal: $0.00
JOIN NOW!
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • Communications
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Poster Contest
      • Scholarships
    • Chapter Awards
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
  • ABOUT US
    • Board of Directors
    • Benefits
    • Volunteering
      • Volunteer Opportunities
      • Communications
      • EDEI Committee
      • Education
      • Emerging Leaders
      • Membership
      • Product Show
      • Social
      • Student Development
      • Women in Pharma®
    • Students
      • Student Chapters
      • Career Workshop
      • Poster Contest
      • Scholarships
    • Chapter Awards
    • Sponsors
    • Contact Us
  • EVENTS
    • Chapter Calendar
    • Educational Programs
    • Social Events
    • Student Activities
    • Product Show
    • Past Events
  • RESOURCES
    • Scholarship Foundation
      • Scholarship Application
    • Podcast
    • Documents
    • Chapter YouTube Channel
    • ISPE Publications
    • ISPE Guidance Documents
    • Member Directory
    • ISPE Training
    • ISPE Communities of Practice
  • BLOG
    • Boston Chapter Blog
      • Contribute
    • ISPE Blog
  • CAREERS
    • Job Board
    • Post a Job
  • Gallery
  • SCHOLARSHIP FOUNDATION
    • About the Foundation
    • Apply for a Scholarship
    • Donate
Mediar Wins $105 Million Financing for Fibrosis Therapies

Mediar Wins $105 Million Financing for Fibrosis Therapies

  • Posted by ISPE Boston
  • On March 16, 2023

Mediar Therapeutics has announced a $105M financing, including a recent $85 million Series A round co-led by Novartis Venture Fund and Sofinnova Partners and with participation from Pfizer Ventures, Bristol Myers Squibb, Eli Lilly & Company, Mass General Brigham Ventures and others. Mediar is advancing a portfolio of first-in-class therapies that halt and even reverse the course of fibrosis.

Mediar was founded on pioneering fibrosis research from Mass General and Brigham and Women’s Hospitals in partnership with Mass General Brigham Ventures with the goal to transform the treatment of fibrotic disease by targeting the myofibroblast, the key cell type driving fibrosis progression.

Mediar’s portfolio comprises three novel targets that are readily detectible in blood and correlate to disease severity, enabling a de-risked approach to clinical development. The series A financing will support advancement of the company’s portfolio of first-in-class antibody treatments, which offer unique potential to address fibrosis at varying stages of the disease, with two programs advancing into human studies in 2024.

Fibrosis contributes to 45 percent of deaths in the industrialized world and is among the most complicated chronic pathologies due to an expansive and complex network of interwoven biological pathways. Current therapeutic approaches mainly focus on the initiators of fibrosis that modulate the underlying immune responses known to drive disease onset. However, the pursuit of these initiators may disrupt related pro-inflammatory pathways that defend the body against illness and can lead to treatment-limiting safety concerns.

Mediar is focused on targeting fibrotic mediators that drive disease progression and potentially avoid the limitations of current approaches. “Mediar brings deep research insights and a robust understanding of fibrotic disease,” said Maina Bhaman, partner at Sofinnova Partners. “These strengths, coupled with a focus on pursuing unexplored pathways that drive fibrosis progression, position the company to change the way the disease is addressed and potentially achieve meaningful therapeutic impact…” (Source: Mediar Therapeutics, 15 March, 2023)

Share on Facebook Share
Share on TwitterTweet
Share on LinkedIn Share
Send email Mail
Print Print
 

0 Comments

Leave Reply Cancel reply

Leave a Comment

Your email address will not be published. Required fields are marked *

Post Categories
  • Industry Buzz (453)
  • Chapter News (422)
  • Knowledge & Training (73)
  • Students & YP (67)
  • Career Tools (11)
Get Updates via Email




Support our Sponsors

Startup Chroma Secures $135M to Advance Epigenetic Editing Technology

Previous thumb

QurAlis Raises $88 Million for Neurodegenerative Disease Treatment

Next thumb
Scroll
Follow Us
Search this Site
@2021 ISPE Boston Chapter. All rights reserved.